Abstract
Keywords
References
Keller KA. Therapeutic review. J Exotic Pet Med. 2011;20(2):156–60.
Francois M, Snoeckx E, Putteman P, Wouters F, De Proost E, Delaet U, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci. 2003;5(1):50–54.
Xiao-cui YE, Jin-lai OU, Bao-xian H, Cui-juan F, Sha L. Preparation and characteristics of itraconazole vaginal thermosensitive in situ gels. J Cent South Pharm. 2014;12(6):551–556.
Zhang HH, Luo QH, Yang ZJ, Pan WS, Nie SF. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Deliv. 2011;18(7): 502–10.
das Neves J. Vaginal delivery of biopharmaceuticals. In: das Neves J, Sarmento B (eds). Mucosal delivery of biopharmaceuticals: biology, challenges and strategies, Springer: New York; 2014. pp. 261–80.
Yi Y, Yoon HJ, Kim BO, Shim M, Kim SO, Hwang SJ, et al. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J Control Release. 2007;117(1):59–67.
Odds FC. Itraconazole: a new oral antifungal agent with a very broad spectrum of activity in superficial and systemic mycoses. J Dermatol Sci. 1993;5(2):65–72.
Sobel JD, Faro S, Force RW. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–211.
Sinem Y, Seda R, Zeynep AY, Esra B. A new in-situ gel formulation of itraconazole for vaginal administration. Pharmacol Pharm. 2012;3:417–426.
Gupta A, Bluhm R. Itraconazole (Sporanox®) for vulvovaginal candidiasis. Skin Ther lett. 2001;7:1–3.
Tian F, Wang YZ, Yang K, Wen CL, Cheng QQ, LI WH, et al. Rheological characteristics of nifeviroc vaginal thermosensitive in situ gels. Chin J New Drugs. 2013;22(3):345–350.
Wang CW, Tang X, Wang XM, Tian XL, LI Z. Preparation of temperature-sensitive nonoxynol-9 sustained-release gel for vagina. Chin J New Drugs. 2006;15(4):281–284.
Puxiang C, Shangrong F. Development in classification, mycology and treatment of vulvovaginal candidiasis. Foreign Med Sci. 2005;16(4):235–237.
Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol. 2000;38(8):2949–54.
Genyan L, Wangsheng Z. In vitro drug sensitivity test of pathogenic fungi. J Clin Labor. 2011;06:406–409.
Yangjun S. In vitro interaction research of tetrandrine combined with azole antifungal agents. Jinan Univ. 2013.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.